Peter DeYoung, CEO, Piramal Pharma Limited

Piramal Pharma Limited

One of the most recent changes at Piramal Pharma Limited is the expansion of its U.S. facility, doubling sterile fill-finish capacity and adding commercial-scale lyophilization to meet growing demand for U.S. containment and antibody-drug conjugate (ADC) support. The company has also enhanced its Science Collective by onboarding senior leaders in discovery and small molecule chemistry, enabling deeper technical collaboration with clients across modalities such as peptides, small molecules, and ADCs. Lastly, their global sustainability and digitalization initiatives have shifted to support future AI-driven manufacturing and quality solutions.

How Piramal as a leading global CDMO is expanding to meet market demands and patient needs

Their seamless integration of facilities and expert team of industry leaders, enabling them to provide comprehensive services across the entire drug life cycle

The role of patient centricity at the heart of their operations, with a goal to reduce the burden of disease for patients worldwide

Videos

Peter DeYoung, CEO at Piramal Pharma Limited, explains how Piramal is meeting the growing demand for integrated biologics manufacturing by expanding capabilities and expertise. 

Peter DeYoung, CEO, Piramal Pharma Limited

Articles